Physician profile
Roger Pafford
NPI 1497802797
$646.94
in general payments reported to CMS, 2019-2025
17 companies · $23.28 in 2025
The $23.28 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $169 · 2022: $78.17 · 2023: $165 · 2025: $23.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $152.09 | 2019-2020 | |
| Kite Pharma, INC. | $67.85 | 2023 | |
| Janssen Biotech, INC. | $64.51 | 2022 | |
| Glaxosmithkline, LLC. | $57.86 | 2023 | |
| Amgen INC. | $41.35 | 2019 | |
| Genzyme Corporation | $38.92 | 2023 | |
| Astellas Pharma US INC | $36.91 | 2019-2020 | |
| Seagen INC. | $35.73 | 2019-2020 | |
| Tesaro, INC. | $29.35 | 2019 | |
| Novo Nordisk INC | $25.77 | 2019-2022 | |
| Inspire Medical Systems, INC. | $23.28 | 2025 | Inspire |
| Pharmacyclics LLC, An Abbvie Company | $13.25 | 2020 | |
| Lilly USA, LLC | $12.69 | 2019 | |
| Pfizer INC. | $11.91 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.85 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $11.82 | 2019 | |
| Puma Biotechnology, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Pafford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.